BNGO - BioNano Genomics Inc Stock Price, Fair Value and News

1.13USD+0.02 (+1.80%)Market Closed

Market Summary

USD1.13+0.02

Market Closed

1.80%

BNGO Stock Price

View Fullscreen

BNGO RSI Chart

BNGO Valuation

Market Cap

75.5M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

2.02

EV/EBITDA

-0.29

Price/Free Cashflow

-0.62

BNGO Price/Sales (Trailing)

BNGO Profitability

EBT Margin

-605.21%

Return on Equity

-274%

Return on Assets

-143.54%

Free Cashflow Yield

-160.05%

BNGO Fundamentals

BNGO Revenue

Revenue (TTM)

37.5M

Rev. Growth (Yr)

18.26%

Rev. Growth (Qtr)

-18.21%

BNGO Earnings

Earnings (TTM)

-226.8M

Earnings Growth (Yr)

15.36%

Earnings Growth (Qtr)

28.41%

Breaking Down BNGO Revenue

Last 7 days

17.7%

Last 30 days

37.8%

Last 90 days

-9.6%

Trailing 12 Months

-83.4%

How does BNGO drawdown profile look like?

BNGO Financial Health

Current Ratio

1.46

BNGO Investor Care

Shares Dilution (1Y)

117.92%

Diluted EPS (TTM)

-6.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	37.5M	0	0	0
2023	29.5M	31.5M	33.6M	36.1M
2022	20.5M	23.3M	25.9M	27.8M
2021	10.5M	13.2M	15.7M	18.0M
2020	9.4M	8.4M	7.3M	8.5M
2019	12.1M	10.9M	11.4M	10.1M
2018	9.6M	10.7M	10.8M	12.0M
2017	0	0	0	9.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BioNano Genomics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 15, 2024	dixon jonathan v.	sold (taxes)	-510	1.27	-402	general counsel
Feb 15, 2024	chaubey alka	sold (taxes)	-1,372	1.27	-1,081	chief medical officer
Feb 15, 2024	oldakowski mark	sold (taxes)	-1,560	1.27	-1,229	chief operating officer
Feb 15, 2024	holmlin r. erik	sold (taxes)	-3,902	1.27	-3,073	president and ceo
Sep 18, 2023	chaubey alka	acquired	-	-	20,000	chief medical officer
Sep 18, 2023	oldakowski mark	acquired	-	-	20,000	chief operating officer
Jun 13, 2023	mamuszka hannah	bought	49,999	0.76	65,789	-
May 16, 2023	holmlin r. erik	bought	9,639	0.6426	15,000	president and ceo
May 12, 2023	oldakowski mark	sold (taxes)	-27,387	0.66	-41,496	chief operating officer
May 12, 2023	holmlin r. erik	sold (taxes)	-33,093	0.66	-50,141	president and ceo

Which funds bought or sold BNGO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	129	45,447	175,184	-%
May 15, 2024	D. E. Shaw & Co., Inc.	sold off	-100	-324,621	-	-%
May 15, 2024	CITADEL ADVISORS LLC	added	18.79	-115,553	266,639	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	CANTOR FITZGERALD, L. P.	sold off	-100	-750,300	-	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	added	385	94.00	145	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-770,003	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-371,260	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	reduced	-27.85	-53,822	39,578	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-80.65	-15,393	1,973	-%

Are Funds Buying or Selling BNGO?

Are funds buying BNGO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BNGO

No. of Funds

Unveiling BioNano Genomics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.88%	1,893,645	SC 13G/A
Jul 07, 2023	blackrock inc.	2.0%	6,136,883	SC 13G/A
Feb 09, 2023	vanguard group inc	5.41%	16,064,444	SC 13G/A
Jan 30, 2023	blackrock inc.	7.8%	23,240,256	SC 13G/A
Feb 09, 2022	vanguard group inc	5.13%	14,825,634	SC 13G
Feb 04, 2022	blackrock inc.	6.5%	18,660,129	SC 13G
Feb 09, 2021	hudson bay capital management lp	1.24%	1,920,000	SC 13G/A
Jan 21, 2021	domain partners viii, l.p.	-	0	SC 13G/A
Feb 14, 2020	sio capital management, llc	4.57%	0	SC 13G/A
Jan 31, 2020	hudson bay capital management lp	7.09%	2,020,000	SC 13G

Recent SEC filings of BioNano Genomics Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 08, 2024	S-8	Employee Benefits Plan
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 08, 2024	424B5	Prospectus Filed
Apr 08, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report
Mar 06, 2024	ARS	ARS
Mar 05, 2024	10-K	Annual Report

Peers (Alternatives to BioNano Genomics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

BioNano Genomics Inc News

Latest updates

BioNano Genomics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-18.2%	8,769,000	10,721,000	9,318,000	8,662,000	7,415,000	8,215,000	7,221,000	6,670,000	5,696,000	6,302,000	4,655,000	3,856,000	3,168,000	3,989,500	2,196,000	1,182,000	1,136,000	2,789,130	3,313,000	2,175,000	1,853,000
Costs and Expenses	23.9%	33,947,000	27,391,000	115,961,000	41,546,000	39,913,000	39,331,500	33,958,000	33,550,000	30,804,000	29,022,000	21,832,000	17,915,000	12,206,000	12,305,000	10,963,000	8,014,000	10,042,000	8,258,864	6,623,000	7,464,000	6,891,000
S&GA Expenses	24.5%	19,536,000	15,690,500	24,896,000	26,936,000	25,976,000	25,320,500	21,216,000	21,783,000	20,277,000	19,806,500	15,327,000	13,829,000	9,528,000	9,428,000	8,659,000	5,613,000	7,368,000	5,859,876	4,449,000	5,056,000	4,791,000
R&D Expenses	-16.4%	9,779,000	11,700,500	13,785,000	14,610,000	13,937,000	14,011,000	12,742,000	11,767,000	10,527,000	9,215,500	6,505,000	4,086,000	2,678,000	2,877,000	2,304,000	2,401,000	2,674,000	2,398,891	2,174,000	2,408,000	2,100,000
EBITDA Margin	8.6%	-5.41	-5.91	-6.31	-4.21	-4.30	-4.34	-4.39	-4.48	-4.52	-4.11	-3.65	-3.55	-	-	-	-	-	-	-	-	-
Interest Expenses	14.7%	5,620,000	4,898,000	71,000	74,000	76,000	74,500	73,000	74,000	77,000	42,000	2,000	268,000	600,000	1,068,000	589,000	561,000	761,000	731,696	578,000	645,000	273,000
Income Taxes	50.0%	-18,000	-36,000	39,000	33,000	26,000	1,805,500	28,000	41,000	9,000	-5,767,000	35,000	9,000	6,000	-11,000	30,000	5,000	5,000	7,548	4,000	5,000	5,000
Earnings Before Taxes	28.4%	-31,440,000	-43,927,000	-112,527,000	-38,879,000	-37,098,000	-36,871,500	-31,781,000	-32,117,000	-29,943,000	-28,716,000	-20,718,000	-18,777,000	-9,941,000	-11,741,000	-10,762,000	-8,069,000	-10,505,000	-7,893,022	-6,394,000	-7,660,000	-7,847,000
EBT Margin	6.0%	-6.05	-6.44	-6.71	-4.59	-4.67	-4.70	-4.73	-4.78	-4.79	-4.35	-3.90	-3.88	-	-	-	-	-	-	-	-	-
Net Income	28.4%	-31,422,000	-43,891,000	-112,566,000	-38,912,000	-37,124,000	-38,677,000	-31,809,000	-32,158,000	-29,952,000	-22,949,000	-20,753,000	-18,786,000	-9,947,000	-11,730,000	-10,792,000	-8,074,000	-10,510,000	-7,900,000	-6,398,000	-7,665,000	-7,852,000
Net Income Margin	6.0%	-6.05	-6.44	-6.76	-4.65	-4.73	-4.77	-4.51	-4.54	-4.51	-4.03	-3.91	-3.88	-	-	-	-	-	-	-	-	-
Free Cashflow	5.5%	-28,131,000	-29,779,000	-26,561,000	-36,977,000	-32,668,000	-34,785,000	-29,741,000	-28,600,000	-32,762,000	-25,890,000	-20,250,000	-12,471,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-26.3%	158	214	182	271	292	308	324	322	348	377	360	357	385	60.00	41.00	27.00	19.00	30.00	19.00	25.00	30.00
Current Assets	-38.9%	86.00	140	105	123	143	157	218	216	242	272	342	342	370	47.00	29.00	25.00	17.00	28.00	18.00	24.00	28.00
Cash Equivalents	-10.0%	16.00	18.00	35.00	15.00	4.00	5.00	28.00	27.00	24.00	25.00	141	333	362	38.00	19.00	17.00	8.00	17.00	8.00	15.00	21.00
Inventory	-13.8%	24.00	28.00	-	32.00	33.00	30.00	25.00	21.00	16.00	12.00	9.00	5.00	3.00	3.00	5.00	3.00	4.00	3.00	3.00	3.00	1.00
Net PPE	8.3%	25.00	23.00	21.00	20.00	19.00	18.00	16.00	14.00	13.00	10.00	9.00	6.00	6.00	5.00	4.00	3.00	2.00	2.00	1.00	1.00	2.00
Goodwill	-	-	-	-	77.00	77.00	77.00	56.00	56.00	56.00	56.00	7.00	7.00	7.00	7.00	7.00	-	-	-	-	-	-
Liabilities	-36.4%	75.00	118	63.00	57.00	61.00	58.00	42.00	37.00	37.00	40.00	18.00	11.00	22.00	25.00	27.00	21.00	23.00	27.00	27.00	27.00	24.00
Current Liabilities	-41.5%	59.00	100	40.00	33.00	38.00	36.00	34.00	28.00	19.00	22.00	18.00	11.00	7.00	9.00	25.00	20.00	23.00	26.00	7.00	8.00	5.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	15.00	16.00	2.00	2.00	-	-	19.00	19.00	18.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.00	14.00	17.00	20.00	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	15.00	16.00	2.00	2.00	-	-	19.00	19.00	18.00
Shareholder's Equity	-13.9%	83.00	96.00	119	215	231	249	282	285	311	337	342	346	363	35.00	15.00	6.00	-	4.00	-	-	6.00
Retained Earnings	-5.4%	-612	-581	-537	-424	-385	-348	-310	-278	-246	-216	-193	-172	-153	-143	-132	-121	-113	-102	-94.68	-88.28	-80.61
Additional Paid-In Capital	2.7%	695	677	656	640	618	599	594	565	559	554	535	518	516	179	147	127	109	106	87.00	87.00	86.00
Shares Outstanding	25.8%	58.00	46.00	35.00	33.00	31.00	30.00	29.00	29.00	28.00	29.00	28.00	28.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	201	-	-	-	400	-	-	-	2,045	-	-	-	27.00	-	-	-	27.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	5.5%	-28,131	-29,779	-26,293	-36,709	-32,400	-34,517	-29,473	-28,332	-32,494	-25,622	-19,982	-12,419	-13,904	-12,104	-10,960	-7,218	-8,032	-9,352	-7,280	-6,316	-6,552
Share Based Compensation	-10.6%	3,015	3,372	3,992	3,932	3,882	5,479	6,059	5,777	5,102	4,802	2,788	1,758	371	451	447	328	328	356	365	336	289
Cashflow From Investing	185.9%	47,586	-55,373	33,427	29,576	16,528	11,610	7,953	31,240	31,964	-92,510	-185,602	74.00	-24.00	-	-2,450	-	-	-23.06	-8.00	-30.00	-
Cashflow From Financing	-131.6%	-21,618	68,484	12,588	17,881	14,862	146	22,651	203	7.00	1,967	13,766	-17,158	337,536	31,686	15,083	16,268	-1,135	18,491	218	811	10,859

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BNGO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 8,769	$ 7,415
Cost of revenue:
Total cost of revenue	5,945	5,345
Operating expenses:
Research and development	9,779	13,937
Selling, general and administrative	19,536	25,976
Restructuring costs	4,632	0
Total operating expenses	33,947	39,913
Loss from operations	(31,123)	(37,843)
Other income (expense):
Interest income	1,044	704
Interest expense	(122)	(76)
Other income (expense)	(1,239)	117
Total other income (expense)	(317)	745
Loss before income taxes	(31,440)	(37,098)
Benefit (provision) for income taxes	18	(26)
Net loss	$ (31,422)	$ (37,124)
Net loss per share, basic (in dollars per share)	$ (0.60)	$ (1.23)
Net loss per share, diluted (in dollars per share)	$ (0.60)	$ (1.23)
Weighted-average common shares outstanding, basic (in shares)	52,739	30,205
Weighted-average common shares outstanding, diluted (in shares)	52,739	30,205
Product revenue
Revenue:
Total revenue	$ 6,828	$ 5,447
Cost of revenue:
Total cost of revenue	4,904	3,858
Service and other revenue
Revenue:
Total revenue	1,941	1,968
Cost of revenue:
Total cost of revenue	$ 1,041	$ 1,487

BNGO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 15,759	$ 17,948
Investments	12,561	48,823
Accounts receivable, net	8,313	9,319
Inventory	19,587	22,892
Prepaid expenses and other current assets	4,945	6,019
Restricted investments	24,446	35,117
Total current assets	85,611	140,118
Restricted cash	400	400
Property and equipment, net	25,279	23,345
Operating lease right-of-use assets	4,870	5,633
Finance lease right-of-use assets	3,453	3,503
Intangible assets, net	31,734	33,974
Other long-term assets	6,648	7,431
Total assets	157,995	214,404
Current liabilities:
Accounts payable	9,844	10,384
Accrued expenses	11,028	8,089
Contract liabilities	1,035	783
Operating lease liability	2,190	2,163
Finance lease liability	269	272
Purchase option liability (at fair value)	5,060	8,534
Convertible notes payable (at fair value)	29,080	69,803
Total current liabilities	58,506	100,028
Operating lease liability, net of current portion	2,755	3,590
Finance lease liability, net of current portion	3,575	3,585
Contingent consideration	10,250	10,890
Long-term contract liabilities	138	154
Total liabilities	75,224	118,247
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value, 400,000,000 shares authorized at March 31, 2024 and December 31, 2023; 57,539,000 and 45,752,000 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	6	5
Additional paid-in capital	695,411	677,337
Accumulated deficit	(612,630)	(581,208)
Accumulated other comprehensive income (loss)	(16)	23
Total stockholders’ equity	82,771	96,157
Total liabilities and stockholders’ equity	$ 157,995	$ 214,404

About BioNano Genomics Inc

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

CEO	Dr. Robert Erik Holmlin M.B.A., Ph.D.
WEBSITE	https://bionano.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	405

BioNano Genomics Inc Frequently Asked Questions

What is the ticker symbol for BioNano Genomics Inc? What does BNGO stand for in stocks?

BNGO is the stock ticker symbol of BioNano Genomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioNano Genomics Inc (BNGO)?

As of Fri May 17 2024, market cap of BioNano Genomics Inc is 75.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BNGO stock?

You can check BNGO's fair value in chart for subscribers.

What is the fair value of BNGO stock?

You can check BNGO's fair value in chart for subscribers. The fair value of BioNano Genomics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioNano Genomics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BNGO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioNano Genomics Inc a good stock to buy?

The fair value guage provides a quick view whether BNGO is over valued or under valued. Whether BioNano Genomics Inc is cheap or expensive depends on the assumptions which impact BioNano Genomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BNGO.

What is BioNano Genomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BNGO's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 2.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BNGO PE ratio will change depending on the future growth rate expectations of investors.